GS
REGN icon

GTS Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

GTS Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Sell
626
-141
-18% -$96K 0.01% 843
2026
Q1 		$593K Sell
767
-349
-31% -$267K 0.02% 650
2025
Q4 		$861K Sell
1,116
-1,387
-55% -$942K 0.03% 505
2025
Q3 		$1.41M Buy
2,503
+1,697
+211% +$960K 0.05% 301
2025
Q2 		$423K Buy
806
+87
+12% +$48.6K 0.02% 731
2025
Q1 		$456K Sell
719
-628
-47% -$432K 0.02% 734
2024
Q4 		$960K Sell
1,347
-3,047
-69% -$2.56M 0.05% 343
2024
Q3 		$4.62M Sell
4,394
-3,345
-43% -$3.72M 0.01% 943
2024
Q2 		$8.13M Buy
7,739
+4,184
+118% +$4.06M 0.02% 586
2024
Q1 		$3.42M Sell
3,555
-183
-5% -$174K 0.01% 1108
2023
Q4 		$3.28M Buy
3,738
+3,143
+528% +$2.59M 0.01% 1293
2023
Q3 		$490K Buy
+595
New +$468K ﹤0.01% 2652

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GTS Securities's REGN Position: Q2 2026 in Review

GTS Securities reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q2 2026, selling an estimated $96K and leaving 626 shares worth $390K. The position accounts for 0.01% of the portfolio, ranked #843.

GTS Securities first reported a position in REGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $8.13M in Q2 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • GTS Securities held 626 shares of Regeneron Pharmaceuticals worth $390K as of Q2 2026.
  • GTS Securities sold 141 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $96K.
  • Regeneron Pharmaceuticals made up 0.01% of GTS Securities's portfolio in Q2 2026, its #843 holding.
  • GTS Securities first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • GTS Securities's Regeneron Pharmaceuticals position peaked at $8.13M in Q2 2024.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.